Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 3310 of 6351
-
New combo treatment may slow colorectal cancer spread
Disease control OngoingThis study aims to assess the clinical benefit of local ablative therapy (LAT) following initial standard first-line systemic treatment including the impact on survival, compared to continued standard first-line systemic treatment for oligometastatic colorectal cancer.
Sponsor: Australasian Gastro-Intestinal Trials Group • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Could low blood pressure be a hidden cause of thinking problems in Parkinson's?
Knowledge-focused Recruiting nowParkinson's disease (PD) is the second most common neurodegenerative disorder worldwide. Besides causing symptoms that impair movement, PD also causes non-motor symptoms, such as problems thinking and orthostatic hypotension (OH), i.e., low blood pressure (BP) when standing. Abou…
Sponsor: University of California, San Diego • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
Phone app aims to help mentally ill smokers kick the habit
Symptom relief OngoingAdults with serious mental illness (SMI) represent 5% of the United States population, yet account for 30% of all cigarettes smoked and are 2 to 3 times more likely to be dependent on nicotine compared with the general population. There are also significant disparities in quittin…
Phase 2 • Sponsor: University of Oklahoma • Aim: Symptom relief
Last updated Jun 27, 2026 12:28 UTC
-
Turmeric and black pepper extract shows promise in slowing early cancers
Disease control CompletedTo explore the use of curcumin and piperine supplementation at a dose of 4 gram/5mg twice a day in early stage prostate cancer patient undergoing active surveillance or patients on observation for MGUS/ low-risk smoldering myeloma.
Phase 2 • Sponsor: University of Rochester • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Ebola vaccine immunity under the microscope: how long does protection last?
Knowledge-focused CompletedDuring the previous Ebola virus disease (EVD) outbreaks, the institute National de Recherche Biomédicale (INRB) and other institutional's staff in Democratic Republic of the Congo (DRC) got vaccinated with the rVSV-ZEBOV vaccine. However, the longevity of Ebola virus (EBOV)-speci…
Sponsor: Institute of Tropical Medicine, Belgium • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
Tweets that tell a story: a new approach to boosting HPV vaccination
Prevention CompletedParents use social media as an important parenting tool and source for health information. Using social media data to examine public opinion has had an early impact in public health and in cancer control and prevention efforts, including about the human papillomavirus (HPV) vacci…
Sponsor: University of Arkansas, Fayetteville • Aim: Prevention
Last updated Jul 29, 2026 00:00 UTC
-
New sickle cell drug shows promise in early safety trial
Disease control CompletedThis is a study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of Pociredir in participants with sickle cell disease.
Phase 1 • Sponsor: Fulcrum Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New online tool aims to ease dementia caregiver stress
Symptom relief CompletedThe WeCareAdvisor is an online tool to help caregivers manage behavioral and psychological symptoms of people living with dementia. The trial will evaluate its efficacy to reduce caregiver distress, improve confidence managing behaviors, as well as reduce occurrences and severity…
Sponsor: Drexel University • Aim: Symptom relief
Last updated Jun 27, 2026 07:52 UTC
-
Gene test could spare men unnecessary biopsies
Knowledge-focused Recruiting nowCondition: Prostate cancer Intervention: Biopsy and inherited risk assessment
Sponsor: Endeavor Health • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:08 UTC
-
New drug HBI-2376 targets Hard-to-Treat cancers in early trial
Disease control OngoingA Phase 1 dose escalation study in patients with advanced solid tumors harboring KRAS or EGFR mutations to determine the maximum tolerated dose and recommended Phase II dose of HBI-2376 and characterize its pharmacokinetic profile.
Phase 1 • Sponsor: HUYABIO International, LLC. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New drug tested for rare brain disease PSP
Disease control CompletedThis is a Phase 2a study to assess the safety and tolerability of TPN-101 patients with PSP.
Phase 2 • Sponsor: Transposon Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New drug duo takes on Hard-to-Treat breast cancer
Disease control OngoingThis is an open-label, Phase 1b dose escalation and expansion study to determine the maximum tolerated dose (MTD) of OP-1250 in combination with palbociclib (Ibrance®️, Pfizer Inc.). Purpose of study is to evaluate the safety and pharmacokinetic (PK) profile, and estimate the prel…
Phase 1 • Sponsor: Olema Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Scientists hunt for sepsis clues in blood genes
Knowledge-focused By invitation onlySepsis is a life-threatening condition caused by the body's overwhelming response to infection, which can lead to organ damage and failure. The goal of this observational study is to better understand the underlying biological changes that occur in patients with sepsis compared t…
Sponsor: Ruijin Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
New program aims to prevent emotional distress after brain injury
Knowledge-focused OngoingThe purpose of the present investigation is to test the efficacy of a brief (6 sessions) dyadic (patient and caregiver together) intervention to prevent chronic emotional distress in at risk dyads admitted to a Neuroscience Intensive Care Unit with an acute brain injury. Through …
Sponsor: Massachusetts General Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
New study tests drug-free pain relief after back surgery to cut opioid use
Symptom relief OngoingThis study will compare the effectiveness of two pain management pathways (standard vs. enriched) for patients undergoing lumbar spine surgery in the Military Health System (MHS). Effectiveness will be based on post-surgery patient-centered outcomes and extent of opioid use. The …
Sponsor: Dan Rhon • Aim: Symptom relief
Last updated Jun 27, 2026 12:38 UTC
-
Can a registry help more families get tested for cancer genes?
Knowledge-focused CompletedThe purpose of this study is to compare the uptake rates of a patient-initiated model of cascade testing with a registry-aided model amongst relatives of patients identified to have a particular cancer predisposition gene. Cascade testing allows the benefits of genetic testing to…
Sponsor: National Cancer Centre, Singapore • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:03 UTC
-
Laughing gas may soothe painful tube insertion in toddlers
Symptom relief CompletedSince nitrous oxide/oxygen mixture is effective to reduce pain and anxiety induced by various painful procedures in children, the investigators hypothesized that its inhalation would reduce pain during nasogastric tube placement in young children. The purpose of this study is to…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Symptom relief
Last updated Jul 03, 2026 00:00 UTC
-
Why COVID-19 lungs fail: tiny blood vessel damage may be key
Knowledge-focused CompletedThe primary endpoint of this research is to establish that the alveolar dead space is significantly higher in patients with COVID-19 ARDS, compared to patients with non-COVID-19 ARDS. Secondarily, the investigators want to establish the prognostic value of the alveolar-dead spac…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jul 10, 2026 00:00 UTC
-
New hope for tough lymphoma: experimental drug ONO-4685 enters human testing
Disease control Recruiting nowThis study will investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ONO-4685 in patients with relapsed or refractory T cell Lymphoma
Phase 1 • Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Can smartphone apps help fight addiction in primary care? large study tests new approach.
Knowledge-focused CompletedThe DIGITS Trial addresses a critical knowledge gap: How to best implement digital treatments for opioids and other substance use disorders in primary care. The DIGITS Trial is a partnership between Kaiser Permanente Washington Health Research Institute (KPWHRI) in Seattle, and K…
Sponsor: Kaiser Permanente • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC